Loading...

Niklas Mattsson, MD, PhD

TitleAssociate Specialist
SchoolUCSF School of Medicine
DepartmentNeurology
Address
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Mattsson N, Zetterberg H, Janelidze S, Insel PS, Andreasson U, Stomrud E, Palmqvist S, Baker D, Tan Hehir CA, Jeromin A, Hanlon D, Song L, Shaw LM, Trojanowski JQ, Weiner MW, Hansson O, Blennow K. Plasma tau in Alzheimer disease. Neurology. 2016 Oct 25; 87(17):1827-1835. PMID: 27694257.
      View in: PubMed
    2. Insel PS, Donohue MC, Mackin RS, Aisen PS, Hansson O, Weiner MW, Mattsson N. Cognitive and functional changes associated with Aß pathology and the progression to mild cognitive impairment. Neurobiol Aging. 2016 Aug 26; 48:172-181. PMID: 27710807.
      View in: PubMed
    3. Insel PS, Palmqvist S, Mackin RS, Nosheny RL, Hansson O, Weiner MW, Mattsson N. Assessing risk for preclinical ß-amyloid pathology with APOE, cognitive, and demographic information. Alzheimers Dement (Amst). 2016; 4:76-84. PMID: 27722193.
      View in: PubMed
    4. Insel PS, Mattsson N, Mackin RS, Schöll M, Nosheny RL, Tosun D, Donohue MC, Aisen PS, Jagust WJ, Weiner MW. Accelerating rates of cognitive decline and imaging markers associated with ß-amyloid pathology. Neurology. 2016 May 17; 86(20):1887-96. PMID: 27164667.
      View in: PubMed
    5. Mattsson N, Insel PS, Donohue M, Jagust W, Sperling R, Aisen P, Weiner MW. Predicting Reduction of Cerebrospinal Fluid ß-Amyloid 42 in Cognitively Healthy Controls. JAMA Neurol. 2015 May; 72(5):554-60. PMID: 25775167.
      View in: PubMed
    6. Ossenkoppele R, Mattsson N, Teunissen CE, Barkhof F, Pijnenburg Y, Scheltens P, van der Flier WM, Rabinovici GD. Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease. Neurobiol Aging. 2015 Aug; 36(8):2340-7. PMID: 25990306; PMCID: PMC4465267.
    7. Durazzo TC, Mattsson N, Weiner MW. Interaction of Cigarette Smoking History With APOE Genotype and Age on Amyloid Level, Glucose Metabolism, and Neurocognition in Cognitively Normal Elders. Nicotine Tob Res. 2016 Feb; 18(2):204-11. PMID: 25847292.
      View in: PubMed
    8. Sacuiu S, Insel PS, Mueller S, Tosun D, Mattsson N, Jack CR, DeCarli C, Petersen R, Aisen PS, Weiner MW, Mackin RS. Chronic Depressive Symptomatology in Mild Cognitive Impairment Is Associated with Frontal Atrophy Rate which Hastens Conversion to Alzheimer Dementia. Am J Geriatr Psychiatry. 2016 Feb; 24(2):126-35. PMID: 26238228.
      View in: PubMed
    9. Insel PS, Mattsson N, Mackin RS, Kornak J, Nosheny R, Tosun-Turgut D, Donohue MC, Aisen PS, Weiner MW. Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease. Ann Clin Transl Neurol. 2015 May; 2(5):534-47. PMID: 26000325; PMCID: PMC4435707.
    10. Mattsson N, Insel PS, Aisen PS, Jagust W, Mackin S, Weiner M. Brain structure and function as mediators of the effects of amyloid on memory. Neurology. 2015 Mar 17; 84(11):1136-44. PMID: 25681451; PMCID: PMC4371407 [Available on 03/17/16].
    11. Mackin RS, Insel P, Zhang J, Mohlenhoff B, Galasko D, Weiner M, Mattsson N. Cerebrospinal fluid a-synuclein and Lewy body-like symptoms in normal controls, mild cognitive impairment, and Alzheimer's disease. J Alzheimers Dis. 2015; 43(3):1007-16. PMID: 25125463; PMCID: PMC4350922.
    12. Mattsson N, Insel PS, Donohue M, Landau S, Jagust WJ, Shaw LM, Trojanowski JQ, Zetterberg H, Blennow K, Weiner MW. Independent information from cerebrospinal fluid amyloid-ß and florbetapir imaging in Alzheimer's disease. Brain. 2015 Mar; 138(Pt 3):772-83. PMID: 25541191; PMCID: PMC4339769 [Available on 03/01/16].
    13. Insel PS, Mattsson N, Donohue MC, Mackin RS, Aisen PS, Jack CR, Shaw LM, Trojanowski JQ, Weiner MW. The transitional association between ß-amyloid pathology and regional brain atrophy. Alzheimers Dement. 2015 Oct; 11(10):1171-9. PMID: 25499535; PMCID: PMC4461550 [Available on 10/01/16].
    14. Skillbäck T, Farahmand B, Bartlett JW, Rosén C, Mattsson N, Nägga K, Kilander L, Religa D, Wimo A, Winblad B, Rosengren L, Schott JM, Blennow K, Eriksdotter M, Zetterberg H. CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. Neurology. 2014 Nov 18; 83(21):1945-53. PMID: 25339208.
      View in: PubMed
    15. Mattsson N, Insel PS, Landau S, Jagust W, Donohue M, Shaw LM, Trojanowski JQ, Zetterberg H, Blennow K, Weiner M. Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease. Ann Clin Transl Neurol. 2014 Aug; 1(8):534-43. PMID: 25356425; PMCID: PMC4184556.
    16. Durazzo TC, Mattsson N, Weiner MW, Korecka M, Trojanowski JQ, Shaw LM. History of cigarette smoking in cognitively-normal elders is associated with elevated cerebrospinal fluid biomarkers of oxidative stress. Drug Alcohol Depend. 2014 Sep 1; 142:262-8. PMID: 25037769; PMCID: PMC4144023.
    17. Mattsson N, Insel PS, Nosheny R, Tosun D, Trojanowski JQ, Shaw LM, Jack CR, Donohue MC, Weiner MW. Emerging ß-amyloid pathology and accelerated cortical atrophy. JAMA Neurol. 2014 Jun; 71(6):725-34. PMID: 24781145; PMCID: PMC4410966.
    18. Durazzo TC, Mattsson N, Weiner MW. Smoking and increased Alzheimer's disease risk: a review of potential mechanisms. Alzheimers Dement. 2014 Jun; 10(3 Suppl):S122-45. PMID: 24924665; PMCID: PMC4098701.
    19. Mattsson N, Tosun D, Insel PS, Simonson A, Jack CR, Beckett LA, Donohue M, Jagust W, Schuff N, Weiner MW. Association of brain amyloid-ß with cerebral perfusion and structure in Alzheimer's disease and mild cognitive impairment. Brain. 2014 May; 137(Pt 5):1550-61. PMID: 24625697; PMCID: PMC3999717.
    20. Mattsson N, Insel P, Tosun D, Zhang J, Jack CR, Galasko D, Weiner M. Effects of baseline CSF a-synuclein on regional brain atrophy rates in healthy elders, mild cognitive impairment and Alzheimer's disease. PLoS One. 2013; 8(12):e85443. PMID: 24392009; PMCID: PMC3877372.
    21. Nagy K, Skagervik I, Tumani H, Petzold A, Wick M, Kühn HJ, Uhr M, Regeniter A, Brettschneider J, Otto M, Kraus J, Deisenhammer F, Lautner R, Blennow K, Shaw L, Zetterberg H, Mattsson N. Cerebrospinal fluid analyses for the diagnosis of subarachnoid haemorrhage and experience from a Swedish study. What method is preferable when diagnosing a subarachnoid haemorrhage? Clin Chem Lab Med. 2013 Nov; 51(11):2073-86. PMID: 23729569.
      View in: PubMed
    22. Mattsson N, Insel P, Nosheny R, Trojanowski JQ, Shaw LM, Jack CR, Tosun D, Weiner M. Effects of cerebrospinal fluid proteins on brain atrophy rates in cognitively healthy older adults. Neurobiol Aging. 2014 Mar; 35(3):614-22. PMID: 24094581; PMCID: PMC3864623.
    23. Mattsson N, Insel P, Nosheny R, Zetterberg H, Trojanowski JQ, Shaw LM, Tosun D, Weiner M. CSF protein biomarkers predicting longitudinal reduction of CSF ß-amyloid42 in cognitively healthy elders. Transl Psychiatry. 2013; 3:e293. PMID: 23962923; PMCID: PMC3756294.
    24. Shahim P, Darin N, Andreasson U, Blennow K, Jennions E, Lundgren J, Månsson JE, Naess K, Törnhage CJ, Zetterberg H, Mattsson N. Cerebrospinal fluid brain injury biomarkers in children: a multicenter study. Pediatr Neurol. 2013 Jul; 49(1):31-39.e2. PMID: 23827424.
      View in: PubMed
    25. Mattsson N, Montelius R, Holtz A, Mouwitz L, Blennow K, Zetterberg H. Coagulation of cerebrospinal fluid--the Nonne-Froin sign. Pract Neurol. 2013 Aug; 13(4):273-4. PMID: 23487811.
      View in: PubMed
    26. Johansson P, Åberg D, Johansson JO, Mattsson N, Hansson O, Ahrén B, Isgaard J, Åberg ND, Blennow K, Zetterberg H, Wallin A, Svensson J. Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer's disease. Psychoneuroendocrinology. 2013 Sep; 38(9):1729-37. PMID: 23473966.
      View in: PubMed
    27. Andreasson U, Lautner R, Schott JM, Mattsson N, Hansson O, Herukka SK, Helisalmi S, Ewers M, Hampel H, Wallin A, Minthon L, Hardy J, Blennow K, Zetterberg H. CSF biomarkers for Alzheimer's pathology and the effect size of APOE ?4. Mol Psychiatry. 2014 Feb; 19(2):148-9. PMID: 23419830; PMCID: PMC3903112.
    28. Bremell D, Mattsson N, Edsbagge M, Blennow K, Andreasson U, Wikkelsö C, Zetterberg H, Hagberg L. Cerebrospinal fluid CXCL13 in Lyme neuroborreliosis and asymptomatic HIV infection. BMC Neurol. 2013; 13:2. PMID: 23294475; PMCID: PMC3546953.
    29. Shahim P, Bochem AE, Mattsson N, Lautner R, Blennow K, Hovingh GK, Motazacker MM, Zetterberg H. Plasma amyloid-ß in patients with Tangier disease. J Alzheimers Dis. 2013; 35(2):307-12. PMID: 23388172.
      View in: PubMed
    30. Mattsson N. ["Fight against aging as a disease"]. Lakartidningen. 2013 Jan 30-Feb 5; 110(5):230-1. PMID: 23451680.
      View in: PubMed
    31. Portelius E, Olsson M, Brinkmalm G, Rüetschi U, Mattsson N, Andreasson U, Gobom J, Brinkmalm A, Hölttä M, Blennow K, Zetterberg H. Mass spectrometric characterization of amyloid-ß species in the 7PA2 cell model of Alzheimer's disease. J Alzheimers Dis. 2013; 33(1):85-93. PMID: 22886024.
      View in: PubMed
    32. Carrillo MC, Blennow K, Soares H, Lewczuk P, Mattsson N, Oberoi P, Umek R, Vandijck M, Salamone S, Bittner T, Shaw LM, Stephenson D, Bain L, Zetterberg H. Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: an update from the Alzheimer's Association Global Biomarkers Consortium. Alzheimers Dement. 2013 Mar; 9(2):137-40. PMID: 23274154.
      View in: PubMed
    33. Johansson P, Almqvist EG, Johansson JO, Mattsson N, Hansson O, Wallin A, Blennow K, Zetterberg H, Svensson J. Reduced cerebrospinal fluid level of thyroxine in patients with Alzheimer's disease. Psychoneuroendocrinology. 2013 Jul; 38(7):1058-66. PMID: 23159010.
      View in: PubMed
    34. Augutis K, Axelsson M, Portelius E, Brinkmalm G, Andreasson U, Gustavsson MK, Malmeström C, Lycke J, Blennow K, Zetterberg H, Mattsson N. Cerebrospinal fluid biomarkers of ß-amyloid metabolism in multiple sclerosis. Mult Scler. 2013 Apr; 19(5):543-52. PMID: 23069872.
      View in: PubMed
    35. Malmeström C, Gillett A, Jernås M, Khademi M, Axelsson M, Kockum I, Mattsson N, Zetterberg H, Blennow K, Alfredsson L, Wadenvik H, Lycke J, Olsson T, Olsson B. Serum levels of LIGHT in MS. Mult Scler. 2013 Jun; 19(7):871-6. PMID: 23037546.
      View in: PubMed
    36. Shahim P, Månsson JE, Darin N, Zetterberg H, Mattsson N. Cerebrospinal fluid biomarkers in neurological diseases in children. Eur J Paediatr Neurol. 2013 Jan; 17(1):7-13. PMID: 23026858.
      View in: PubMed
    37. Sachse D, Bolstad N, Jonsson M, Sæves I, Johansson CB, Delezuch W, Hagve M, Hardang IM, Isaksson HS, Ivarsson A, Lehto L, Keikkala E, Mattsson N, Ranta JK, Stavelin A, Sudmann AA, Varsi K. The Accu-Chek Mobile blood glucose monitoring system used under controlled conditions meets ISO 15197 standards in the hands of diabetes patients. Scand J Clin Lab Invest. 2012 Sep; 72(5):374-9. PMID: 22900743.
      View in: PubMed
    38. Hölttä M, Zetterberg H, Mirgorodskaya E, Mattsson N, Blennow K, Gobom J. Peptidome analysis of cerebrospinal fluid by LC-MALDI MS. PLoS One. 2012; 7(8):e42555. PMID: 22880031; PMCID: PMC3412831.
    39. Bartlett JW, Frost C, Mattsson N, Skillbäck T, Blennow K, Zetterberg H, Schott JM. Determining cut-points for Alzheimer's disease biomarkers: statistical issues, methods and challenges. Biomark Med. 2012 Aug; 6(4):391-400. PMID: 22917141.
      View in: PubMed
    40. Brinkmalm G, Portelius E, Öhrfelt A, Mattsson N, Persson R, Gustavsson MK, Vite CH, Gobom J, Månsson JE, Nilsson J, Halim A, Larson G, Rüetschi U, Zetterberg H, Blennow K, Brinkmalm A. An online nano-LC-ESI-FTICR-MS method for comprehensive characterization of endogenous fragments from amyloid ß and amyloid precursor protein in human and cat cerebrospinal fluid. J Mass Spectrom. 2012 May; 47(5):591-603. PMID: 22576872.
      View in: PubMed
    41. Rosén C, Andreasson U, Mattsson N, Marcusson J, Minthon L, Andreasen N, Blennow K, Zetterberg H. Cerebrospinal fluid profiles of amyloid ß-related biomarkers in Alzheimer's disease. Neuromolecular Med. 2012 Mar; 14(1):65-73. PMID: 22350541.
      View in: PubMed
    42. Movérare-Skrtic S, Johansson P, Mattsson N, Hansson O, Wallin A, Johansson JO, Zetterberg H, Blennow K, Svensson J. Leukocyte telomere length (LTL) is reduced in stable mild cognitive impairment but low LTL is not associated with conversion to Alzheimer's disease: a pilot study. Exp Gerontol. 2012 Feb; 47(2):179-82. PMID: 22210159.
      View in: PubMed
    43. Lautner R, Mattsson N, Schöll M, Augutis K, Blennow K, Olsson B, Zetterberg H. Biomarkers for microglial activation in Alzheimer's disease. Int J Alzheimers Dis. 2011; 2011:939426. PMID: 22114747; PMCID: PMC3206374.
    44. Wall M, Mattsson N, Zetterberg H, Blennow K. [Automated cerebrospinal fluid cell count. A valuable contribution to diagnostics of brain diseases]. Lakartidningen. 2011 Oct 5-11; 108(40):1972-3. PMID: 22111239.
      View in: PubMed
    45. Mattsson N, Zetterberg H, Bianconi S, Yanjanin NM, Fu R, Månsson JE, Porter FD, Blennow K. Miglustat treatment may reduce cerebrospinal fluid levels of the axonal degeneration marker tau in niemann-pick type C. JIMD Rep. 2012; 3:45-52. PMID: 23430872; PMCID: PMC3509856.
    46. Johansson P, Johansson JO, Labrie F, Mattsson N, Hansson O, Blennow K, Zetterberg H, Wallin A, Ohlsson C, Svensson J. Mild dementia is associated with increased adrenal secretion of cortisol and precursor sex steroids in women. Clin Endocrinol (Oxf). 2011 Sep; 75(3):301-8. PMID: 21521348.
      View in: PubMed
    47. Hesse C, Johansson I, Mattsson N, Bremell D, Andreasson U, Halim A, Anckarsäter R, Blennow K, Anckarsäter H, Zetterberg H, Larson G, Hagberg L, Grahn A. The N-terminal domain of a-dystroglycan, released as a 38 kDa protein, is increased in cerebrospinal fluid in patients with Lyme neuroborreliosis. Biochem Biophys Res Commun. 2011 Sep 2; 412(3):494-9. PMID: 21843510.
      View in: PubMed
    48. Mattsson N, Olsson B, Andreasson U, Portelius E, Zetterberg H. Found in translation: a blood-based test for Niemann-Pick type C1. Biomark Med. 2011 Apr; 5(2):201. PMID: 21473724.
      View in: PubMed
    49. Mattsson N, Olsson B, Andreasson U, Portelius E, Zetterberg H. It is all about clearance. Biomark Med. 2011 Apr; 5(2):202. PMID: 21614802.
      View in: PubMed
    50. Mattsson N, Olsson B, Andreasson U, Portelius E, Zetterberg H. Growth factors in Parkinson's disease. Biomark Med. 2011 Apr; 5(2):201-2. PMID: 21614801.
      View in: PubMed
    51. Mattsson N, Olsson B, Andreasson U, Portelius E, Zetterberg H. Troponin T: more than acute myocardial infarction. Biomark Med. 2011 Apr; 5(2):203. PMID: 21612120.
      View in: PubMed
    52. Mattsson N, Olsson B, Andreasson U, Portelius E, Zetterberg H. A new member in the biomarker discovery toolbox. Biomark Med. 2011 Apr; 5(2):202. PMID: 21612119.
      View in: PubMed
    53. Rosén C, Mattsson N, Johansson PM, Andreasson U, Wallin A, Hansson O, Johansson JO, Lamont J, Svensson J, Blennow K, Zetterberg H. Discriminatory Analysis of Biochip-Derived Protein Patterns in CSF and Plasma in Neurodegenerative Diseases. Front Aging Neurosci. 2011; 3:1. PMID: 21442044; PMCID: PMC3057441.
    54. Johansson P, Mattsson N, Hansson O, Wallin A, Johansson JO, Andreasson U, Zetterberg H, Blennow K, Svensson J. Cerebrospinal fluid biomarkers for Alzheimer’s disease: diagnostic performance in a homogeneous mono-center population. J Alzheimers Dis. 2011; 24(3):537-46. PMID: 21297262.
      View in: PubMed
    55. Portelius E, Mattsson N, Andreasson U, Blennow K, Zetterberg H. Novel aß isoforms in Alzheimer's disease - their role in diagnosis and treatment. Curr Pharm Des. 2011; 17(25):2594-602. PMID: 21728980.
      View in: PubMed
    56. Zetterberg H, Mattsson N, Blennow K, Olsson B. Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease. Alzheimers Res Ther. 2010; 2(6):32. PMID: 21122172; PMCID: PMC3031878.
    57. Constantinescu R, Andreasson U, Li S, Podust VN, Mattsson N, Anckarsäter R, Anckarsäter H, Rosengren L, Holmberg B, Blennow K, Wikkelsö C, Rüetschi U, Zetterberg H. Proteomic profiling of cerebrospinal fluid in parkinsonian disorders. Parkinsonism Relat Disord. 2010 Sep; 16(8):545-9. PMID: 20620095.
      View in: PubMed
    58. Zetterberg H, Mattsson N, Blennow K. Cerebrospinal fluid analysis should be considered in patients with cognitive problems. Int J Alzheimers Dis. 2010; 2010:163065. PMID: 21487447; PMCID: PMC2911653.
    59. Mattsson N, Zetterberg H, Blennow K. Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease. Int J Alzheimers Dis. 2010; 2010. PMID: 20721354; PMCID: PMC2915803.
    60. Mattsson N, Brax D, Zetterberg H. To know or not to know: ethical issues related to early diagnosis of Alzheimer's disease. Int J Alzheimers Dis. 2010; 2010. PMID: 20798843; PMCID: PMC2925376.
    61. Zetterberg H, Mattsson N, Shaw LM, Blennow K. Biochemical markers in Alzheimer's disease clinical trials. Biomark Med. 2010 Feb; 4(1):91-8. PMID: 20387305.
      View in: PubMed
    62. Mattsson N, Zetterberg H. Alzheimer's disease and CSF biomarkers: key challenges for broad clinical applications. Biomark Med. 2009 Dec; 3(6):735-7. PMID: 20477711.
      View in: PubMed
    63. Mattsson N, Blennow K, Zetterberg H. CSF biomarkers: pinpointing Alzheimer pathogenesis. Ann N Y Acad Sci. 2009 Oct; 1180:28-35. PMID: 19906258.
      View in: PubMed
    64. Mattsson N, Yaong M, Rosengren L, Blennow K, Månsson JE, Andersen O, Zetterberg H, Haghighi S, Zho I, Pratico D. Elevated cerebrospinal fluid levels of prostaglandin E2 and 15-(S)-hydroxyeicosatetraenoic acid in multiple sclerosis. J Intern Med. 2009 Apr; 265(4):459-64. PMID: 19019188.
      View in: PubMed
    65. Zetterberg H, Pedersen M, Lind K, Svensson M, Rolstad S, Eckerström C, Syversen S, Mattsson UB, Ysander C, Mattsson N, Nordlund A, Vanderstichele H, Vanmechelen E, Jonsson M, Edman A, Blennow K, Wallin A. Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years. J Alzheimers Dis. 2007 Nov; 12(3):255-60. PMID: 18057559.
      View in: PubMed
    66. Mattsson N, Haghighi S, Andersen O, Yao Y, Rosengren L, Blennow K, Praticò D, Zetterberg H. Elevated cerebrospinal fluid F2-isoprostane levels indicating oxidative stress in healthy siblings of multiple sclerosis patients. Neurosci Lett. 2007 Mar 13; 414(3):233-6. PMID: 17227694.
      View in: PubMed
    67. Björnsson E, Abrahamsson H, Simrén M, Mattsson N, Jensen C, Agerforz P, Kilander A. Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial. Aliment Pharmacol Ther. 2006 Sep 15; 24(6):945-54. PMID: 16948806.
      View in: PubMed
    68. Mattsson N, Kilander A, Björnsson E. [Helicobacter pylori can in rare cases be the cause of iron and vitamin B 12 deficiency. No increased risk of iron and vitamin B 12 deficiency due to proton pump inhibitors]. Lakartidningen. 2004 Jun 3; 101(23):2014-5. PMID: 15232839.
      View in: PubMed
    Niklas's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _
    Back to TOP